This is a Notice of Intent, not a request for proposal. The NIH Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Takeda Pharmaceutical Company Limited for Gammagard S/D. The NIH-CC Pharmacy plans to purchase 10 bottles each of Gammagard S/D 10 gm and 5 gm kits, plus as-needed supply, to support patient care. Takeda is identified as the only responsible source for Gammagard S/D, which is on the Clinical Center formulary and must remain available to maintain consistent treatment for current and potential patients.